QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.107.123224v1 322/2/701    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winkler, M. Articles by Quast, U. Search for Related Content PubMed PubMed Citation Articles by Winkler, M. Articles by Quast, U.

ENDOCRINE AND DIABETES

Testing the Bipartite Model of the Sulfonylurea Receptor Binding Site: Binding of A-, B-, and A + B-Site Ligands

Department of Pharmacology and Toxicology, Medical Faculty, University of Tübingen, Tübingen, Germany

Received for publication March 22, 2007
Accepted May 9, 2007.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
ATP-sensitive K⁺ (K_ATP) channels are composed of pore-forming subunits (Kir6.x) and of regulatory subunits, the sulfonylurea receptors (SURx). Subtypes of K_ATP channels are expressed in different organs. The sulfonylureas and glinides (insulinotropes) close the K_ATP channel in pancreatic -cells and stimulate insulin secretion. The insulinotrope binding site of the pancreatic channel (Kir6.2/SUR1) consists of two overlapping (sub)-sites, site A, located on SUR1 and containing Ser1237 (which in SUR2 is replaced by Tyr1206), and site B, formed by SUR1 and Kir6.2. Insulinotropes bind to the A-, B-, or A + B-site(s) and are grouped accordingly. A-ligands are highly selective in closing the pancreatic channel, whereas B-ligands are nonselective and insensitive to the mutation S1237Y. We have examined the binding of insulinotropes representative of the three groups in [³H]glibenclamide competition experiments to determine the contribution of Kir6.x to binding affinity, the effect of the mutation Y1206S in site A of SUR2, and the subtype selectivity of the compounds. The results show that the bipartite nature of the SUR1 binding site applies also to SUR2. Kir6.2 as part of the B-site may interact directly or allosterically with structural elements common to all insulinotropes, i.e., the negative charge and/or the adjacent phenyl ring. The B-site confers a moderate subtype selectivity on B-ligands. The affinity of B-ligands is altered by the mutation SUR2(Y1206S), suggesting that the mutation affects the binding chamber of SUR2 as a whole or subsite A, including the region where the subsites overlap.

View larger version (21K): [in this window] [in a new window]   Fig. 1. The bipartite structure of the insulinotrope binding site of Kir6.2/SUR1. The two (sub)sites are highlighted in black. To the A-site, located on the second transmembrane domain (TMD 2) of SUR1, contribute transmembrane segments 14, 15, and parts of the attached cytosolic loops. The strategic residue Ser1237 located in the loop connecting segments 15 and 16 is presented by the dot (Ashfield et al., 1999; Babenko et al., 1999; Uhde et al., 1999) The B-(sub)site involves (parts of) the cytosolic loop 3 (CL3), which connects TMD 0 and 1 (Mikhailov et al., 2001; Vila-Carriles et al., 2007) and the amino terminus of Kir6.2 (Vila-Carriles et al., 2007). NBF, nucleotide binding fold.

View larger version (17K): [in this window] [in a new window]   Fig. 2. Structure and classification of the sulfonylureas and glinides used in this study. Compounds are aligned according to the negative charge and the adjacent phenyl ring both common to all insulinotropes and are grouped as binding to subsite(s) A and/or B. The subsites, represented by the black bars, overlap to accommodate the common elements; the amino acid residues interacting with them are not known. Regarding the B-site, also unknown are the residues interacting with the coupling unit (-NH-CO- or -CO-NH-) and with the distal phenyl ring of the B-ligand; the piperidino substituent present in repaglinide and AZ-DF may interact with the N terminus of Kir6.2 (Stephan et al., 2006; Vila-Carriles et al., 2007).

The selectivity and the classification of the insulinotropes were established for the pancreatic channel, Kir6.2/SUR1, and mostly by studying channel inhibition (Ashfield et al., 1999; Proks et al., 2002). Here, we sought to investigate the binding process and to evaluate to which degree the bipartite model of the insulinotrope binding site of the pancreatic channel extends to the cardiovascular channels. Therefore, the binding properties of 10 insulinotropes were characterized in [³H]glibenclamide competition assays. The compounds comprised three A-ligands (including nateglinide), three A + B-ligands, and four B-ligands [meglitinide and UL-DF 9 (i.e., the "B-parts" derived from glibenclamide and gliquidone), and two piperidino-glinides, repaglinide and AZ-DF 265, with a piperidino substituent attached to the carboxamido part; Fig. 2]. We evaluated the effect of coexpression with Kir6.x on the affinity of SURx for the insulinotropes, the effect of the mutation SUR2(Y1206S), i.e., the reverse of the mutation SUR1(S1237Y), and the selectivity in binding to the recombinant pancreatic, myocardial, and vascular K_ATP channels. The results show that the bipartite organization of the insulinotrope binding site can be extended to Kir6.x/SUR2 with minor modifications.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Materials. [³H]Glibenclamide (specific activity, 1.85 TBq/mmol) was purchased from PerkinElmer Life Sciences (Bad Homburg, Germany). The reagents and media used for cell culture and transfection were from Invitrogen (Karlsruhe, Germany). Glibenclamide was purchased from Sigma (Deisenhofen, Germany). Repaglinide was a gift from Novo Nordisk (Bagsvaerd, Denmark) or purchased from Toronto Research Chemicals (Toronto, ON, Canada). The following compounds were gifts from the respective companies: (–)AZ-DF 265 and UL-DF 9 (Boehringer Ingelheim GmbH, Ingelheim, Germany), glibornuride (Roche, Basel, Switzerland), gliclazide (Servier, Paris, France), glimepiride and meglitinide (Sanofi-Aventis, Frankfurt, Germany), gliquidone (Yamanouchi Pharmaceuticals, Heidelberg, Germany), and nateglinide (Novartis Pharma, Basel, Switzerland). The opener, P1075, was from Leo Pharmaceuticals (Ballerup, Denmark) or Tocris/Biozol (Eching, Germany). The K_ATP channel modulators were dissolved in dimethyl sulfoxide/ethanol (50/50, v/v) and further diluted with the same solvent or with incubation buffer (final solvent concentration < 1%).

Cell Culture and Transfection. HEK 293 cells were cultured in minimum essential medium containing glutamine and supplemented with 10% fetal bovine serum and 20 µg/ml gentamicin as described previously (Hambrock et al., 1998, 2001). Cells were transfected with rat SUR1 (GenBank accession no. X97279 [GenBank] ) or the murine clones of SUR2A (D86037 [GenBank] ), SUR2B (D86038 [GenBank] ), Kir6.1 (D88159), or Kir6.2 (D50581 [GenBank] ) using the pcDNA 3.1 (+) vector, Lipofectamine 2000, and Opti-MEM (Invitrogen) according to the manufacturer's instructions (Hambrock et al., 1998, 2001). The mutants SUR2A(Y1206S) and SUR2B(Y1206S) were prepared as described previously (Hambrock et al., 2001; Stephan et al., 2005). For transient coexpression, cells were transfected with Kir and SUR at a molar plasmid ratio of 1:1. To improve the signal/noise ratio in the [³H]glibenclamide binding assays to Kir6.1/SUR2B channels, an HEK cell line permanently expressing the channel was generated as described by Giblin et al. (1999).

[³H]Glibenclamide Competition Experiments. Binding experiments were performed in intact cells at 37°C as described previously (Hambrock et al., 2001), using an incubation buffer containing 129 mM NaCl, 5 mM KCl, 1.2 mM MgCl₂, 1.25 mM CaCl₂, 11 mM D-(+)-glucose, 5 mM NaHCO₃, and 10 mM HEPES at pH 7.4 and supplemented with [³H]glibenclamide [2 nM (SUR1) or 4–5 nM (SUR2)] and the unlabeled inhibitor. Experiments were started by addition of cells (0.1–0.6 mg protein/ml) to give a volume of 1 ml. After an incubation time of 30 min, the reaction was stopped by diluting 0.3-ml aliquots (in triplicate) in 10 ml of ice-cold quench solution [50 mM Tris-(hydroxymethyl)-aminomethane, 154 mM NaCl, pH 7.4]. Bound and free ligands were separated by rapid filtration over Whatman GF/C filters (Whatman International, Maidstone, UK). Filters were washed twice with quench solution and counted for [³H] in the presence of 4.5 ml of scintillant (Ultima Gold; Packard, Meriden, CT). At higher concentrations (e.g., glibenclamide > 100 nM), the inhibitors interfered with [³H]glibenclamide binding to intrinsic binding sites in HEK cells, and this was particularly evident in experiments with SUR2. Complete binding curves were either dissected by two component analysis with the high-affinity component representing binding to SUR2 or by defining specific [³H]glibenclamide binding as the binding displaced by P1075 (100 µM). Both methods gave identical results (see e.g., Russ et al., 1999; Hambrock et al., 2001; Löffler-Walz et al., 2002). Nonspecific binding ranged from 40 to 60% of total binding (SUR2); in the case of SUR1, nonspecific binding was determined in the presence of 100 nM glibenclamide and was approximately 10%. The maximal number of [³H]glibenclamide sites (B_max values) were between 0.4 and 1.5 pmol/mg protein according to the transfectant and the method used (permanent versus transient transfection).

Data Analysis. Binding inhibition curves were analyzed according to the equation:

(1)

with y denoting specific binding, n as the Hill coefficient, and x as the inhibitor concentration with px =–log x and pIC₅₀ =–log IC₅₀. Curve analysis gave Hill coefficients 1 and the respective IC₅₀ values with their 95% confidence intervals. IC₅₀ values were corrected for the presence of the radioligand according to the Cheng-Prusoff equation (Cheng and Prusoff, 1973) giving the inhibition constants, K_i:

(2)

Here, L denotes the concentration and K_d denotes the equilibrium dissociation constant of the radioligand; in the case of homogeneous displacement, this reduces to K_i = K_d = IC₅₀ – L.

Data are shown as means ± S.E.M. Fits of eq. 1 to the data were performed according to the method of least-squares using the program SigmaPlot 9.0 (SPSS Science, Chicago, IL). Individual experiments were analyzed, and the parameters were averaged assuming that amplitudes and pIC₅₀ values were normally distributed (Christopoulos, 1998). In the text, K_d/K_i values are given followed by the 95% confidence interval in parentheses. Linear correlation analysis was performed using the pK_i values. In calculations involving two mean values with S.E.s, propagation of errors was taken into account according to Bevington (1969). Significance of differences between two normally distributed parameters with equal variance was assessed using the two-tailed unpaired Student's t test.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Binding to SURx and Effect of Coexpression. Figure 3 illustrates the inhibition of [³H]glibenclamide binding to SUR and K_ATP channel subtypes by glibenclamide, repaglinide, and nateglinide, i.e., by A + B-, B-, and A-ligands, respectively. Experiments were performed at 37°C in intact cells to have an intact cell interior present; in particular, the cytoskeleton (Löffler-Walz and Quast, 1998) and physiological nucleotide concentrations (Hambrock et al., 2002). Inhibition curves were regular with a Hill coefficient of 1 and gave the pK_i values listed in Tables 1 and 2. pK_i values are directly related to binding affinity, with an increase by 1 log unit corresponding to a binding energy of 1.4 kcal/mol (Berg et al., 2002).

View larger version (31K): [in this window] [in a new window]   Fig. 3. Inhibition of (specific) [3H]glibenclamide binding by glibenclamide (GBC), repaglinide (REP), and nateglinide (NAT) in HEK cells expressing SURs (left) and KATP channels (right) as indicated. Data are pooled from three to five experiments each and are shown as mean S.E.M. pIC50 values were derived by fitting eq. 1 in Materials and Methods to the data and were corrected for the presence of the radioligand (Cheng-Prusoff correction, eq. 2). In case of SUR2, some data points at high insulinotrope concentrations were below the inhibition curve due to interference with [3H]glibenclamide binding to low-affinity sites intrinsic to HEK cells (see Materials and Methods). These points were omitted from curve analysis. [3H]glibenclamide concentration ranged from 2 (Kir6.2/SUR1) to 5 (Kir6.1/SUR2B) nM, and total binding was typically 250 to 500 fmol/mg protein. Nonspecific binding was determined in the presence of 100 nM glibenclamide (SUR1) or 100 µM P1075 (SUR2; see Materials and Methods) and ranged from 10% (SUR1) to 60% [SUR2B(YS)].

Figure 3 (top panels) presents the curves of the three ligands binding to SUR1 and Kir6.2/SUR1. The large leftward shift of the repaglinide curve upon coexpression is striking, and Tables 1 and 2 show that, in the presence of Kir6.2, the K_i for binding of repaglinide to SUR1 was decreased (i.e., affinity increased) by a factor of 10^2.1 130 (see also Hansen et al., 2005; Stephan et al., 2006). An even larger shift was determined for the other piperidino-glinide, AZ-DF 265 (370x; Tables 1 and 2). The pK_i values of all insulinotropes are compared in Fig. 4a. With the exception of the two piperidino-glinides, all values fell on a straight line with slope 1 and at a distance of 0.52 from the line of identity (Table 3). This means that coexpression with Kir6.2 decreased K_i for binding of insulinotropes to SUR1 by the factor of 10^0.52 = 3.3, the exception being the piperidino-glinides.

View larger version (16K): [in this window] [in a new window]   Fig. 4. Correlation analysis illustrating the effect of coexpression with Kir6.2 on the affinity of insulinotropes for SUR1 (a) and SUR2A(YS) (b). pKi values are listed in Tables 1 and 2, numbering of compounds in Table 1, and results of correlation analysis (r2, slope, and d = distance from the line of identity) in Table 3. The broken and the solid lines represent the line of identity and the best fit with slope 1, respectively.

View larger version (15K): [in this window] [in a new window]   Fig. 5. Correlation analyses. a, comparison of insulinotrope binding to the wild-type and the mutant myocardial channel to show the effect of the mutation SUR2(Y1206S). b and c, comparison of the binding affinities of insulinotropes for KATP channel subtypes. b, Kir6.2/SUR2A on Kir6.2/SUR1; c, Kir6.1/SUR2B on Kir6.2/SUR1. pKi values are given in Table 2, numbering of compounds in Table 1; the results of correlation analysis are listed in Table 3.

In addition, the selectivity of the insulinotropes in binding to the SUR subtypes expressed alone was examined. Comparing SUR1 and SUR2A(YS), it was found that the A- and A + B-ligands were, in the mean, 3.5-fold selective for SUR1 (Table 3). In contrast, UL-DF showed a 3-fold selectivity for SUR2A(YS), whereas meglitinide and the piperidino-glinides showed no preference (Table 1). Very similar results were obtained for the comparison of SUR1 with SUR2B(YS). Table 3 also shows that there was no selectivity in binding of the insulinotropes to mutants SUR2A and 2B.

The Mutation Y1206S in SUR2. Figure 5a compares binding to the wild type and the mutant myocardial channel. The pK_i values of A- and A + B-ligands were on a line with slope 1 shifted leftwards from the line of identity by 1.12 U. This showed that the mutation decreased the K_i values of the A- and A + B-ligands 13-fold (Table 3). Of the B-ligands, the K_i values of the piperidino-glinides remained essentially unchanged; in contrast, the K_i values of meglitinide and UL-DF were increased (i.e., affinity decreased) 3.5- and 7.1-fold, respectively (Fig. 5a; Table 2). Similar results were found for the mutation of the vascular channel. In the mean, K_i values of the A- and A + B-ligands were decreased 19x (Table 3), whereas those of the B-ligands (with the exception of repaglinide) were slightly increased by the mutation (<4x; Table 2).

It was also examined whether the insulinotropes discriminated between the mutant cardiovascular channels, Kir6.2/SUR2A(YS) and Kir6.1/SUR2B(YS). Correlation analysis showed that the two piperidino-glinides were 20-fold, and the other compounds 2.6-fold selective for the myocardial channel (Table 3; P < 0.05).

Subtype-Selective Binding to Wild-Type Channels. Figure 5b compares binding to the pancreatic and myocardial channels. The pK_i values of the A- and A + B-ligands were on a line shifted rightwards from the line of identity by 1.29 ± 0.08 U (Table 3), showing that these compounds were 19-fold selective for the pancreatic channel. Again, the B-ligands did not form a homogenous group; meglitinide and repaglinide were essentially nonselective, whereas AZ-DF was 7x pancreas- and UL-DF 14x cardioselective.

Similar results were obtained when binding to the pancreatic and the vascular channels was compared. Figure 5c and Table 3 show that the pK_i values of the A- and A + B-ligands exhibited a 10^1.88 = 76-fold preference for the -cell channel. This selectivity was shared by AZ-DF; repaglinide was less selective for the -cell channel (21x), whereas meglitinide was nonselective, and UL-DF was 5-fold selective for the vascular channel (Table 2; Fig. 5c). When the selectivity of the compounds for the myocardial versus the vascular K_ATP channel was analyzed, the pK_i values of all compounds with the exception of the A-ligands, glibornuride and nateglinide, fell on a line with slope 1 and gave a selectivity of 6 for the myocardial over the vascular channel (Table 3). In contrast, glibornuride and nateglinide were entirely nonselective.

Finally, long sulfonylureas were compared with their corresponding B-ligands, i.e., glibenclamide with meglitinide and gliquidone with UL-DF (Fig. 2). The K_i ratios, defined as K_i(B)/K_i(A + B) for the pancreatic, myocardial, and vascular channel, were 7100, 135, and 66 for the first pair and 13,500, 26, and 10 for the second pair, respectively (Table 2).

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
Coexpression with Kir6.x. A major result of this study is that coexpression with Kir6.x increased the affinity of SURx for all insulinotropes and that, at a given subtype, the A- and the A + B-ligands were affected to exactly the same degree (Table 3). The latter result is surprising because the Kir6.2 N terminus is part of the B-site (Vila-Carriles et al., 2007; see Fig. 1), and one would expect that A-ligands should not be affected by the presence of Kir. An attractive explanation is that the A- and B-sites overlap to accommodate the negative charge and the adjacent phenyl ring common to all insulinotropes (Fig. 2) and that the Kir6.2 N terminus may either be part of the acceptor site for these elements or interact with this site allosterically.

Another point concerns the small contribution of coexpression to the binding affinity of the A- and A + B-ligands to SUR (2.6–6.8x according to SUR and Kir subtype). This corresponds to the contribution of a single hydrogen bond at most (1–3 kcal/mol). Hence, if favorable contacts are made between the amino terminus of Kir and the ligand, this enthalpic contribution to the energy of binding must be essentially canceled out by a negative entropic balance due to fixation of the ligand and/or parts of the protein.

The B-ligands were differentially affected by coexpression; meglitinide and UL-DF resembled the A- and A + B-ligands, whereas for the piperidino-glinides, the effect was large for Kir6.2/SUR1 (also see Hansen et al., 2005) and smaller for the other combinations. This peculiar behavior depends on the piperidino-substituent, and it makes a major contribution to the selectivity of repaglinide (and AZ-DF) for the pancreatic over the cardiovascular K_ATP channels (Stephan et al., 2006). With the amino terminus of Kir6.2 being part of the B-site, one might speculate that it either interacts directly with the piperidino group or that it induces a conformation in a subcompartment of the B-site that is able to interact with this group.

It is also of interest to consider the differences between coexpression of SURx with Kir6.1 versus Kir6.2. There was no difference in insulinotrope binding to SUR2A(YS) and SUR2B(YS); however, with the respective mutant channels, Kir6.2/SUR2A(YS) versus Kir6.1/SUR2B(YS), the insulinotropes were 2.6-fold selective for the cardiac channel with the exception of the piperidino-glinides, which were 20-fold selective (see above). This shows that with respect to insulinotrope binding, Kir6.2 couples more efficiently to SUR2 than Kir6.1 and that the piperidino-glinides are exquisitely sensitive to this difference.

The Mutation SUR2(Y1206S). The mutation of Ser1237 in the A-site of SUR1 to Tyr (the corresponding amino acid in SUR2) abolishes both high-affinity binding of glibenclamide to SUR1 and high-affinity channel closure by the A-ligands, tolbutamide and nateglinide (Ashfield et al., 1999; Chachin et al., 2003); however, channel closure by the B-ligands, meglitinide and repaglinide, remained unaffected (Ashfield et al., 1999; Hansen et al., 2002). The dramatic effect of this mutation in SUR1 contrasts with the moderate effects of the inverse mutation Y1206S in SUR2, which increases the binding affinity of the myocardial and vascular channels for A- and A + B-ligands 13 and 19x, respectively, and the sensitivity of the cardiovascular channels to block by glibenclamide 30x (Stephan et al., 2005). Obviously, in SUR1, Ser1237 is essential for the ability of the A-site to interact with A-ligands, whereas these ligands bind to the SUR2 containing channels at still reasonable concentrations (Table 2). Regarding the A-site of SUR2, amino acids other than Tyr1206 (which weakens the interaction with the A-ligands) contribute to the site to allow binding, and, for all SURs, binding to the A-site is enhanced by the presence of the amino terminus of Kir6.2 (see above).

Surprisingly, the mutation Y1206S produced also (moderate) effects on the binding of B-ligands. The most striking case was UL-DF, whose affinity for the myocardial channel was decreased seven times. As another example, the mutation reduced the preference of most insulinotropes (including UL-DF and meglitinide) for the myocardial over the vascular channel from 6 to 2.6x but increased that of the piperidinoglinides to 20x. Two conclusions may be drawn. First, the mutation in the A-site of SUR2 seemingly affects the conformation of the binding pocket as a whole (i.e., A + B) or the A-site including the region where the two sites overlap. Second, and as noted above for the effect of coexpression, the heterogeneous response of the B-ligands to the mutation shows that the B-site has two subcompartments, one occupied by all B-ligands and an additional subcompartment for the piperidino moiety of repaglinide and AZ-DF. This is in contrast to the A- and A + B-ligands, which were homogeneous in all aspects. Collectively, the results show that the bipartite nature of the insulinotrope binding site, established for SUR1, extends also to SUR2.

Subtype Selectivity. Previous electrophysiological, radioligand binding, and photoaffinity labeling studies suggest that the interaction of an insulinotrope with the A-site of SURx determines the subtype specificity, whereas the B-site is similar in all Kir6.2/SURx subtypes and is, therefore, permissive (Ashfield et al., 1999; Proks et al., 2002; Vila-Carriles et al., 2007). In this study, the dominant role of the A-site for selectivity is highlighted by the comparison of A + B-ligands with their cognate B-ligands, i.e., the pairs glibenclamide-meglitinide and gliquidone-UL-DF. The K_i ratios of the two pairs were 10,000 at the pancreatic but <100 at the cardiovascular channels. Table 2 shows that this decrease is caused mainly by high selectivity of the A + B-ligand for pancreatic channel, i.e., by the differential interaction of the long sulfonylureas with the A-site of SURx, which, in turn, hinges mostly on the change from Ser1237 in SUR1 to Tyr1206 in SUR2 (Ashfield et al., 1999). Regarding the permissive nature of the B-site, the results of this study show that the B-site can afford (moderate) subtype selectivity as shown by the following examples: comparing binding to the pancreatic and myocardial channels, selectivity ranged from 14x cardio- (UL-DF) to 7x pancreas-selective (AZ-DF), and AZ-DF bound with 70x higher affinity to the pancreatic than to the vascular channel (Table 2).

Binding and Effect. The A- (and A + B-ligands) were 19-fold selective for binding to the pancreatic as compared with the myocardial and 76-fold with the vascular K_ATP channel. These values are much lower than those determined in electrophysiological studies, in particular for the A-ligands. The concentrations of e.g., tolbutamide (Gribble et al., 1998), gliclazide (Gribble and Ashcroft, 1999), and nateglinide (Chachin et al., 2003) required to inhibit the recombinant cardiac and/or smooth muscle channels are very similar to those that block the channel by binding to the pore (which is formed by Kir6.2). Hence, it is impossible to decide whether it is the binding of these A-ligands to SUR2 or to Kir6.2 that closes the channel, and it may well be that binding to SUR2 is not transduced into channel closure, i.e., that it is "nonproductive." A major difference in signal transduction between SUR1- and SUR2-containing channels lies in the differential effect of Mg²⁺ salts of nucleotides, in particular MgADP, on the inhibitory action of insulinotropes; inhibition of Kir6.2/SUR1 channels is enhanced by nucleotides but that of Kir6.2/SUR2 channels unchanged or reduced (Gribble et al., 1998; Reimann et al., 2003). Conspicuously, this difference is paralleled by a 2x higher ATPase activity of the second nucleotide-binding domain of SUR1 as compared with that of SUR2A (Masia et al., 2005).

In conclusion, the results of this binding study show that the bipartite model of the insulinotrope binding site established for Kir6.2/SUR1 extends also to Kir6.x/SUR2. The A-site of SUR dominates the subtype selectivity of insulinotrope binding, but the B-site can confer moderate selectivity to B-ligands. The B-site in SUR2 senses the mutation Y1206S in the A-site and the amino terminus of Kir6.2 (which is part of the B-site) may accept in part the functional groups present in all active insulinotropes, i.e., the central phenyl ring and the negative charge.

	Acknowledgements

 
We thank Y. Kurachi and Y. Horio (Osaka, Japan) for the generous gift of the murine clones of SUR2A, SUR2B, and Kir6.x, C. Derst (Jena) for rat SUR1, A. Hambrock (Tübingen, Germany) for preparing the Y1206S mutants of SUR2A and 2B, and U. Russ (Tübingen) for help with the preparation of the manuscript.

	Footnotes

 
This study was supported by the Deutsche Forschungsgemeinschaft (Qu 100/3-2).

Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

doi:10.1124/jpet.107.123224.

ABBREVIATIONS: K_ATP, ATP-sensitive K⁺; Kir, inwardly rectifying K⁺ channel; SUR, sulfonylurea receptor; UL-DF 9, 4-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolyl)-ethyl]benzoic acid; AZ-DF 265, 4-[[N-(-phenyl-2-piperidino-benzyl)carbamoyl]methyl]-benzoic acid; P1075, N-cyano-N'-(1,1-dimethylpropyl)-N''-3-pyridylguanidine; HEK, human embryonic kidney.

Address correspondence to: Dr. Ulrich Quast, Department of Pharmacology and Toxicology, Medical Faculty, University of Tübingen, Wilhelmstrasse 56, D-72074 Tübingen, Germany. E-mail: ulrich.quast{at}uni-tuebingen.de

	References

Top Abstract Materials and Methods Results Discussion References

 

Aguilar-Bryan L and Bryan J (1999) Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 20: 101–135.[Abstract/Free Full Text]
Ashfield R, Gribble FM, Ashcroft SJH, and Ashcroft FM (1999) Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K_ATP channel. Diabetes 48: 1341–1347.[Abstract]
Babenko AP, Gonzalez G, and Bryan J (1999) The tolbutamide site of SUR1 and a mechanism for its functional coupling to K_ATP channel closure. FEBS Lett 459: 367–376.[CrossRef][Medline]
Berg JM, Tymoczko JL, and Stryer L (2002) Biochemistry, W.H. Freeman and Company, New York.
Bevington PR (1969) Data Reduction and Error Analysis for the Physical Sciences, McGraw-Hill, New York.
Brown GR and Foubister AJ (1984) Receptor binding sites of hypoglycemic sulfonylureas and related [(acylamino)alkyl]benzoic acids. J Med Chem 27: 79–81.[CrossRef][Medline]
Bryan J, Crane A, Vila-Carriles WH, Babenko AP, and Aguilar-Bryan L (2005) Insulin secretagogues, sulfonylurea receptors and K_ATP channels. Curr Pharm Design 11: 2699–2716.[CrossRef][Medline]
Chachin M, Yamada M, Fujita A, Matsuoka T, Matsushita K, and Kurachi Y (2003) Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic -cell-type K_ATP channels. J Pharmacol Exp Ther 304: 1025–1032.[Abstract/Free Full Text]
Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50% inhibition (IC₅₀) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108.[CrossRef][Medline]
Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol Sci 19: 351–357.[CrossRef][Medline]
Dabrowski M, Wahl P, Holmes WE, and Ashcroft FM (2001) Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 44: 747–756.[CrossRef][Medline]
Giblin JP, Leaney JL, and Tinker A (1999) The molecular assembly of ATP-sensitive potassium channels: determinants on the pore forming subunit. J Biol Chem 274: 22652–22659.[Abstract/Free Full Text]
Gribble FM and Ashcroft FM (1999) Differential sensitivity of beta-cell and extrapancreatic K_ATP channels to gliclazide. Diabetologia 42: 845–848.[CrossRef][Medline]
Gribble FM and Reimann F (2003) Sulphonylurea action revisited: the post-cloning era. Diabetologia 46: 875–891.[CrossRef][Medline]
Gribble FM, Tucker SJ, Seino S, and Ashcroft FM (1998) Tissue specificity of sulfonylureas: studies on cloned cardiac and -cell K_ATP channels. Diabetes 47: 1412–1418.[Abstract/Free Full Text]
Hambrock A, Löffler-Walz C, Kurachi Y, and Quast U (1998) Mg²⁺ and ATP dependence of K_ATP channel modulator binding to the recombinant sulphonylurea receptor, SUR2B. Br J Pharmacol 125: 577–583.[CrossRef][Medline]
Hambrock A, Löffler-Walz C, and Quast U (2002) Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides. Br J Pharmacol 136: 995–1004.[CrossRef][Medline]
Hambrock A, Löffler-Walz C, Russ U, Lange U, and Quast U (2001) Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes. Mol Pharmacol 60: 190–199.[Abstract/Free Full Text]
Hansen AMK, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, and Wahl P (2002) Differential interactions of nateglinide and repaglinide on the human -cell sulphonylurea receptor 1. Diabetes 51: 2789–2795.[Abstract/Free Full Text]
Hansen AMK, Hansen JB, Carr RD, Ashcroft FM, and Wahl P (2005) Kir6.2-dependent high-affinity repaglinide binding to -cell K_ATP channels. Br J Pharmacol 144: 551–557.[CrossRef][Medline]
Löffler-Walz C, Hambrock A, and Quast U (2002) Interaction of K_ATP channel modulators with sulfonylurea receptor SUR2B: implication for tetramer formation and allosteric coupling of subunits. Mol Pharmacol 61: 407–414.[Abstract/Free Full Text]
Löffler-Walz C and Quast U (1998) Disruption of the actin cytoskeleton abolishes high affinity ³H-glibenclamide binding in rat aortic rings. Naunyn Schmiedebergs Arch Pharmacol 357: 183–185.[CrossRef][Medline]
Masia R, Enkvetchakul D, and Nichols CG (2005) Differential nucleotide regulation of K_ATP channels by SUR1 and SUR2A. J Mol Cell Cardiol 39: 491–501.[CrossRef][Medline]
Mikhailov MV, Mikhailova EA, and Ashcroft SJH (2001) Molecular structure of the glibenclamide binding site of the -cell K-ATP channel. FEBS Lett 499: 154–160.[CrossRef][Medline]
Proks P, Reimann F, Green N, Gribble F, and Ashcroft F (2002) Sulfonylurea stimulation of insulin secretion. Diabetes 51 (Suppl 3): S368–S376.[Abstract/Free Full Text]
Quast U, Stephan D, Bieger S, and Russ U (2004) The impact of ATP-sensitive K⁺ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 53: S156–S164.[Abstract/Free Full Text]
Reimann F, Dabrowski M, Jones P, Gribble FM, and Ashcroft FM (2003) Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K⁺ (K_ATP) channels by Mg-nucleotides. J Physiol 547: 159–168.[Abstract/Free Full Text]
Rufer C and Losert W (1979) Blood glucose lowering sulfonamides with asymmetric carbon atoms: III. Related N-substituted carbamoylbenzoic acids. J Med Chem 22: 750–752.[CrossRef][Medline]
Russ U, Hambrock A, Artunc F, Löffler-Walz C, Horio Y, Kurachi Y, and Quast U (1999) Coexpression with the inward rectifier K⁺ channel Kir6.1 increases the affinity of the vascular sulfonylurea receptor SUR2B for glibenclamide. Mol Pharmacol 56: 955–961.[Abstract/Free Full Text]
Seino S and Miki T (2003) Physiological and pathophysiological roles of ATP-sensitive K⁺ channels. Prog Biophys Mol Biol 81: 133–176.[CrossRef][Medline]
Stephan D, Stauß, Lange U, Felsch H, Löffler-Walz C, Hambrock A, Russ U, and Quast U (2005) The mutation Y1206S increases the affinity of the sulphonylurea receptor SUR2A for glibenclamide and enhances the effects of coexpression with Kir6.2. Br J Pharmacol 144: 1078–1088.[CrossRef][Medline]
Stephan D, Winkler M, Kühner P, Russ U, and Quast U (2006) Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K_ATP channels. Diabetologia 49: 2039–2048.[CrossRef][Medline]
Sturgess NC, Ashford ML, Cook DL, and Hales CN (1985) The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 2: 474–475.[Medline]
Uhde I, Toman A, Gross I, Schwanstecher C, and Schwanstecher M (1999) Identification of the potassium channel opener site on sulfonylurea receptors. J Biol Chem 274: 28079–28082.[Abstract/Free Full Text]
Vila-Carriles WH, Zhao G, and Bryan J (2007) Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels. FASEB J 21: 18–25.[Abstract/Free Full Text]

This article has been cited by other articles:

				K. S.C. Hamming, D. Soliman, L. C. Matemisz, O. Niazi, Y. Lang, A. L. Gloyn, and P. E. Light Coexpression of the Type 2 Diabetes Susceptibility Gene Variants KCNJ11 E23K and ABCC8 S1369A Alter the ATP and Sulfonylurea Sensitivities of the ATP-Sensitive K+ Channel Diabetes, October 1, 2009; 58(10): 2419 - 2424. [Abstract] [Full Text] [PDF]

				M. Winkler, R. Lutz, U. Russ, U. Quast, and J. Bryan Analysis of Two KCNJ11 Neonatal Diabetes Mutations, V59G and V59A, and the Analogous KCNJ8 I60G Substitution: DIFFERENCES BETWEEN THE CHANNEL SUBTYPES FORMED WITH SUR1 J. Biol. Chem., March 13, 2009; 284(11): 6752 - 6762. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.107.123224v1 322/2/701    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Winkler, M. Articles by Quast, U. Search for Related Content PubMed PubMed Citation Articles by Winkler, M. Articles by Quast, U.